临床试验结果的背景化:38,510名RECOVERY试验参与者与英格兰346,271名COVID-19住院患者参考人群的基线特征和结局比较
本研究比较了在英格兰招募的RECOVERY试验参与者(n=38,510)与同期英格兰COVID-19住院参考人群(n=346,271)的基线特征和28天全因死亡率。RECOVERY参与者更年轻且女性比例更低,年龄和性别调整后的28天死亡率在两组间总体相似,但随时间变化显著,仅在第一波疫情期间RECOVERY组调整后死亡率较低。结论认为RECOVERY的绝对效应估计对该目标人群广泛适用,但应结合当前死亡率估计进行解读。
要点
- RECOVERY参与者平均年龄62.6岁,参考人群65.7岁;女性比例分别为37%和45%。
- 年龄和性别调整后28天死亡率RECOVERY为23.7%,参考人群为24.8%,总体相似。
- 仅2020年3月至5月第一波疫情期间RECOVERY组调整后死亡率较低。
核心结论
- RECOVERY试验的年龄和性别调整后28天死亡率与同期英格兰全国COVID-19住院参考人群相似,但两组死亡率均随时间大幅变化。
- RECOVERY的绝对效应估计在当时对该目标人群广泛适用,但应结合当前死亡率估计进行解读。
研究设计与样本
- 比较RECOVERY试验在英格兰招募的参与者(n=38,510)与2020年3月至2021年11月英格兰COVID-19住院参考人群(n=346,271)的基线特征和死亡率。
- 使用两队列的关联住院和死亡数据提取人口学、合并症/衰弱评分以及粗率和年龄性别调整的28天全因死亡率。
主要发现
- RECOVERY参与者平均年龄62.6(标准差15.3)岁,参考人群65.7(标准差18.5)岁;女性比例分别为37%和45%。
- RECOVERY参与者的合并症和衰弱评分较低,但年龄分层后差异减弱。
- 年龄和性别调整后28天死亡率随时间下降,两组间总体相似:RECOVERY 23.7%(95%CI 23.3-24.1%)vs 参考人群24.8%(95%CI 24.6-25.0%)。
- 仅在英国第一波疫情期间(2020年3月至5月),RECOVERY组调整后死亡率低于参考人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomised trials are essential to reliably assess medical interventions. Nevertheless, interpretation of such studies, particularly when considering absolute effects, is enhanced by understanding how the trial population may differ from the populations it aims to represent. METHODS: We compared baseline characteristics and mortality of RECOVERY participants recruited in England (n = 38,510) with a reference population hospitalised with COVID-19 in England (n = 346,271) from March 2020 to November 2021. We used linked hospitalisation and mortality data for both cohorts to extract demographics, comorbidity/frailty scores, and crude and age- and sex-adjusted 28-day all-cause mortality. RESULTS: Demographics of RECOVERY participants were broadly similar to the reference population, but RECOVERY participants were younger (mean age [standard deviation]: RECOVERY 62.6 [15.3] vs reference 65.7 [18.5] years) and less frequently female (37% vs 45%). Comorbidity and frailty scores were lower in RECOVERY, but differences were attenuated after age stratification. Age- and sex-adjusted 28-day mortality declined over time but was similar between cohorts across the study period (RECOVERY 23.7% [95% confidence interval: 23.3-24.1%]; vs reference 24.8% [24.6-25.0%]), except during the first pandemic wave in the UK (March-May 2020) when adjusted mortality was lower in RECOVERY. CONCLUSIONS: Adjusted 28-day mortality in RECOVERY was similar to a nationwide reference population of patients admitted with COVID-19 in England during the same period but varied substantially over time in both cohorts. Therefore, the absolute effect estimates from RECOVERY were broadly applicable to the target population at the time but should be interpreted in the light of current mortality estimates. TRIAL REGISTRATION: ISRCTN50189673- Feb. 04, 2020, NCT04381936- May 11, 2020.
引用
- Pessoa-Amorim G, Goldacre R, Crichton C, et al. Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England. Trials. 2024. PMID: 38951929. doi:10.1186/s13063-024-08273-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。